COVID-19 UPDATE: All elective surgeries and procedures are cancelled until further notice. Please see our latest visitor policy. If you think you may have been exposed or have symptoms, please call your provider before visiting one of our locations. For more information, please visit our online COVID-19 Information Center or call the Montefiore-Einstein COVID-19 Hotline: 1-844-444-CV19 (1-844-444-2819).

ACTUALIZACIÓN SOBRE EL COVID-19: Todas las cirugías y operaciones quedan canceladas hasta nuevo aviso. Lea nuestras nuevas normas para visitas. Si cree que podría haber estado en contacto con la enfermedad o si presenta síntomas, por favor llame a su proveedor antes de acudir a cualquiera de nuestros centros. Más información en nuestro Centro de Información en Línea sobre el COVID-19 o llamando a la línea informativa Montefiore-Einstein de COVID-19: 1-844-444-CV19 (1-844-444-2819).

Espanol
Research
Home >  Cancer (Oncology) >  Research and Clinical Trials >  Research
Print

Research and Clinical Trials

Research

Montefiore Einstein Center for Cancer Care physicians are on the leading edge of life-changing research. The partnership with our Albert Einstein College of Medicine has resulted in broad synergies and collaborations that advance clinical and translational research to accelerate the pace that new discoveries become the treatments and therapies that benefit patients.

Below is a sampling of our most recent research studies:

Advancements in Lung Cancer Care

February 1, 2017

Nitin Ohri, MD, Attending Physician, Radiation Oncology, Montefiore, and Assistant Professor, Radiation Oncology, Einstein and his research team recently concluded a study on pretreatment positron emission tomography as a tool for identifying lesions at risk for progression after concurrent chemoradiation therapy for locally advanced non-small cell lung cancer.

Read the International Journal of Radiation Oncology, Biology, Physics Article

Exploring New Possibilities in Squamous Cell Carcinoma Treatment

January 9, 2017

Drs. Madhur Garg and Joseph Sparano led a team of researchers in a study to determine whether adding cetuximab to chemoradiation would reduce locoregional failure rates in squamous cell carcinoma of the anal canal.

Read the Journal of Clinical Oncology Article

Novel Biomarker Shows Promise in Early-stage Breast Cancer

December 12, 2016

Joseph A. Sparano, MD, Vice-Chairman, Medical Oncology, Montefiore Einstein Center for Cancer Care, discusses a study his team conducted which found that a biomarker for breast cancer metastasis was associated with cancer occurrence. The study analyzed tumors from 600 patients with early-stage breast cancer who had undergone surgery, adjuvant chemotherapy and endocrine therapy.

Read the Cancer Therapy Advisor Article   Watch the ASCO Post Segment

New Drug Combo Shows Promise Curbing Tough-to-Treat Breast Cancer

December 7, 2016

Noah S. Kornblum, MD, attending physician, Montefiore Einstein Center for Cancer Care, describes a phase II study his team presented at the San Antonio Breast Cancer Symposium that found a new drug combination can improve survival rates for people suffering from a common form of breast cancer. The treatment would help keep cancer at bay longer, from five months to 10 months, by reducing estrogen in the body and slowing cancer growth.

Watch the OncLive.com Segment   Read the MedPage Today Article

Interruption of Radiation Therapy Risks Cancer Recurrence

February 11, 2016

Madhur Garg, MD, clinical director and Nitin Ohri, MD, attending physician, Department of Radiation Oncology, Montefiore Einstein Center for Cancer Care, discuss a new study their team conducted that found missing two appointments of radiotherapy may impair tumor control, particularly for head and neck cancers. The findings demonstrated that noncompliance to scheduled appointments can pose a cancer recurrence risk. Noncompliance to scheduled treatments may also represent a new behavioral biomarker for identifying high-risk patients who require additional interventions to achieve optimal care outcomes.

Read the ASCO Post Evening News Article